- Acasti Pharma reported a net loss of $3.432 million for QQ2 2025 with no revenue recognized in the quarter. Operating expenses totaled $4.831 million, dominated by research and development ($2.976 million) and general and administrative costs ($1.853 million). EBITDA was negative $4.829 million, and net income declined to $-3.432 million, reflecting continued burn in a period with no top-line growth.
- The company shows strong short-term liquidity metrics (current ratio 6.01, cash per share $1.32) despite the ongoing cash burn. These liquidity levels imply a runway contingent on continued funding, partnerships, or licensing deals for CaPre and other cardiovascular initiatives.
- Management commentary in QQ2 2025 is constrained by the lack of revenue and the uncertain near-term commercialization path. The strategic focus remains the pursuit of strategic partnerships for CaPre and the broader pipeline, with no formal forward guidance disclosed in the filing. Investors should weigh the potential for value creation through licensing versus continued dilution risk and ongoing burn.